Press Releases

Filters
September 23, 2024

Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association

Read more
September 12, 2024

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-Based Radiopharmaceutical Programs Targeting Solid Tumors

Read more
September 10, 2024

Debiopharm pose la première pierre de son nouveau bâtiment pouvant accueillir jusqu’à 300 collaborateurs tout en sortant des énergies fossilles…

Read more
September 9, 2024

First Patients Dosed in Debiopharm’s Phase III Trial (LIBELULA) Investigating Debio 4326, A 12-Month Triptorelin Formulation for Children with Central…

Read more
August 27, 2024

Debiopharm Underlines Commitment to Eradicating Antimicrobial Resistance by Sponsoring the 8th Annual World AMR Conference

Read more
June 24, 2024

Le challenge qualité de vie du patient tient les 5 finalistes de sa 9ème édition. Chaque projet reçoit la récompense…

Read more
June 3, 2024

Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family

Read more
May 28, 2024

MEDSIR & DEBIOPHARM Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer

Read more
April 30, 2024

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1B Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1…

Read more